CFTR and cystic fibrosis: All clinical trialsto date using Ga(III) as an antibacterial agenthave been designed for patients suffering from CF, an autosomal recessivegenetic disorder characterized by mutations of the CF transmembraneconductance regulator (CFTR) gene.